Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Availability of monkeypox vaccinations for low and middle-income countries: Challenges and recommendations
Ist Teil von
Travel medicine and infectious disease, 2022-11, Vol.50, p.102473-102473, Article 102473
Ort / Verlag
Netherlands: Elsevier Ltd
Erscheinungsjahr
2022
Quelle
Access via ScienceDirect (Elsevier)
Beschreibungen/Notizen
Dear Editor, Since July 2022, the current monkeypox (MPX) multi-country outbreak has been declared a public health emergency of international concern (PHEIC) [1], and as of September 14, 2022, 59,147 confirmed and 489 suspected cases, including 22 deaths, have been reported to the World Health Organization (WHO). The ongoing outbreak is alarming because it is the first time since the discovery of monkeypox virus (MPXV) that there has been a widespread incidence of new cases in non-endemic countries outside of Africa. Since the first confirmed case of this outbreak in the UK in May 2022, the virus has spread globally, and the cases have been reported from 103 WHO member states [2]. Lessons may be learned from the COVID-19 vaccine development experiences, which resulted in a vast manufacturing capability globally [6]. Because there is practically only one MPX vaccine manufacturer, exporting technology to developing nations might assist secure enough supply for them while also contributing to global inventory [7].